1: Sigel CW, Macklin AW, Woolley JL Jr, Johnson NW, Collier MA, Blum MR, Clendeninn NJ, Everitt BJ, Grebe G, Mackars A, et al. Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. NCI Monogr. 1987;(5):111-20. PubMed PMID: 3431588.
2: Rosowsky A, Mota CE, Wright JE, Queener SF. 2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity. J Med Chem. 1994 Dec 23;37(26):4522-8. PubMed PMID: 7799402.
3: de Vries EG, Gietema JA, Workman P, Scott JE, Crawshaw A, Dobbs HJ, Dennis I, Mulder NH, Sleijfer DT, Willemse PH. A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer. Br J Cancer. 1993 Sep;68(3):641-4. PubMed PMID: 8353055; PubMed Central PMCID: PMC1968400.
4: Lassiter LK, Tummala MK, Hussain MH, Stadler WM, Petrylak DP, Carducci MA. Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy. Clin Genitourin Cancer. 2008 Mar;6(1):31-5. doi: 10.3816/CGC.2008.n.005. PubMed PMID: 18501080.
5: Laszlo J, Brenckman WD Jr, Morgan E, Clendeninn NJ, Williams T, Currie V, Young C. Initial clinical studies of piritrexim. NCI Monogr. 1987;(5):121-5. PubMed PMID: 3323908.
6: de Wit R, Kaye SB, Roberts JT, Stoter G, Scott J, Verweij J. Oral piritrexim, an effective treatment for metastatic urothelial cancer. Br J Cancer. 1993 Feb;67(2):388-90. PubMed PMID: 8431372; PubMed Central PMCID: PMC1968166.
7: Perkins W, Williams RE, Vestey JP, Tidman MJ, Layton AM, Cunliffe WJ, Saihan EM, Klaber MR, Manna VK, Baker H, et al. A multicentre 12-week open study of a lipid-soluble folate antagonist, piritrexim in severe psoriasis. Br J Dermatol. 1993 Nov;129(5):584-9. PubMed PMID: 8251356.
8: Kovacs JA, Allegra CJ, Swan JC, Drake JC, Parrillo JE, Chabner BA, Masur H. Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate. Antimicrob Agents Chemother. 1988 Apr;32(4):430-3. PubMed PMID: 2967669; PubMed Central PMCID: PMC172195.
9: Adamson PC, Balis FM, Miser J, Wells RJ, Bleyer WA, Williams TE, Gillespie A, Penta JS, Clendeninn NJ, Poplack DG. Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule. Cancer Res. 1990 Aug 1;50(15):4464-7. PubMed PMID: 2369724.
10: Gangjee A, Zhu Y, Queener SF. 6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents. J Med Chem. 1998 Nov 5;41(23):4533-41. PubMed PMID: 9804692.
11: Guzzo C, Benik K, Lazarus G, Johnson J, Weinstein G. Treatment of psoriasis with piritrexim, a lipid-soluble folate antagonist. Arch Dermatol. 1991 Apr;127(4):511-4. PubMed PMID: 2006875.
12: Richards RG, Brown OE, Gillison ML, Sedwick WD. Drug concentration-dependent DNA lesions are induced by the lipid-soluble antifolate, piritrexim (BW301U). Mol Pharmacol. 1986 Dec;30(6):651-8. PubMed PMID: 3491287.
13: Woolley JL, Deangelis DV, Grace ME, Liao SH, Crouch RC, Sigel CW. The disposition and metabolism of [14C]piritrexim in dogs after intravenous and oral administration. Drug Metab Dispos. 1991 Nov-Dec;19(6):1139-46. PubMed PMID: 1687022.
14: Feun LG, Savaraj N, Benedetto P, Hanlon J, Sridhar KS, Collier M, Richman S, Liao SH, Clendeninn NJ. Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies. J Natl Cancer Inst. 1991 Jan 2;83(1):51-5. PubMed PMID: 1984518.
15: Bleehen NM, Newman HV, Rampling RP, Ramsay JR, Roberts JT, Bedford P, Nethersell AB. A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma. Br J Cancer. 1995 Sep;72(3):766-8. PubMed PMID: 7669591; PubMed Central PMCID: PMC2033879.
16: Woolley JL, Deangelis DV, Crouch RC, Shockcor JP, Sigel CW. The disposition and metabolism of [14C]piritrexim in rats after intravenous and oral administration. Drug Metab Dispos. 1991 May-Jun;19(3):600-8. PubMed PMID: 1680625.
17: Chan DC, Rosowsky A. Synthesis of the lipophilic antifolate piritrexim via a palladium(0)-catalyzed cross-coupling reaction. J Org Chem. 2005 Feb 18;70(4):1364-8. PubMed PMID: 15704971.
18: Woolley JL Jr, Ringstad JL, Sigel CW. Competitive protein binding assay for piritrexim. J Pharm Sci. 1989 Sep;78(9):749-52. PubMed PMID: 2585269.
19: Chan DC, Fu H, Forsch RA, Queener SF, Rosowsky A. Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain. J Med Chem. 2005 Jun 30;48(13):4420-31. PubMed PMID: 15974594.
20: Lai JP, He XW, Chen F. Separation and determination of the antitumor drug piritrexim by molecularly imprinted microspheres in high-performance liquid chromatography. Anal Bioanal Chem. 2003 Sep;377(1):208-13. Epub 2003 Jul 4. PubMed PMID: 12845402.